BOCA RATON REGIONAL HOSPITAL

Common Drug Interactions

Emmanuel Markakis, PharmD Clinical Manager / PGY1 Residency Director Boca Raton Regional Hospital Boca Raton, Florida


Objectives

- Review the mechanisms of drug interactions
- Discuss the most common medications involved in drug interactions at BRRH
- Discuss other predispositions for drug interaction potential
- Review strategies to assist in minimizing drug interactions

Definition

- Drug-Drug Interaction:
 - It is the modification of the effect of one drug (the object drug) by the prior or concomitant administration of another (precipitant drug).
 - May be unintended or intended
 - Various forms of interactions

Risk Factors for Drug Interactions




BOCA RATON REGIONAL HOSPITAL

Risk Factors for Drug Interactions

Productivity of the pharma industry

O

Finding the true cost of a new drug is complex and controversial...



Data: USFDA, PhRMA

Akshat Rathi | theconversation.com

* New drug cost and R&D spend could be 30% higher if non-PhRMA members are included

Drugs Withdrawn or Not Approved in the U.S. Because of Interactions

- Examples of Drugs Withdrawn
 - Terfenadine (Seldane)
 - Astemizole (Hismanal)
 - Cisapride (Propulsid)



Examples of Drugs Not Approved
Domperidone

Not All Drug Interactions are Bad: Protease Inhibitors

Drug Affected	Ritonavir	Saquinavir*	Nelfinavir
Indinavir (IDV)	Levels: IDV ♦ 2-5x Dose: IDV 400 mg bid + RTV 400 mg bid, or IDV 800 mg bid + RTV 100 or 200 mg bid	Levels: IDV no effect, SQV 4-7x † Dose: Insufficient data	Levels: IDV ↑ 50%, NFV ↑ 80% Dose: Limited data for IDV 1,200 mg bid + NFV 1,250 mg bid
Ritonavir (RTV)	-	Levels: RTV no effect SQV • 20x † Dose: Invirase or Fortovase 400 mg bid + RTV 400 mg bid	Levels: RTV no effect NFV 1.5x Dose: RTV 400 mg bid + NFV 500-750 mg bid
Saquinavir (SQV)	-	-	Levels: SQV † 3-5x, NFV † 20%† Dose: Standard NFV Fortovase 800 mg tid or 1,200 mg bid
Nelfinavir (NFV)	-	-	-
Amprenavir (APV)	-	-	-

Not All Drug Interactions are Bad: Protease Inhibitors

Drug Affected	Amprenavir	Lopinavir + Ritonavir
Indinavir (IDV)	Levels: APV AUC † 33% Dose: no change	Levels: IDV AUC and Cmin increased. Dose: IDV 600 mg bid
Ritonavir (RTV)	Levels: APV AUC \$ 2.5-fold Dose: Limited data for APV 600-1,200 mg bid + RTV 100-200 mg bid	Lopinavir is co-formulated with ritonavir as Kaletra.
Saquinavir (SQV)	Levels: APV AUC↓32% Dose: insufficient data	Levels: SQV† AUC and Cmin increased Dose: SQV 800 mg bid, LPV/r standard
Nelfinavir (NFV)	Levels: APV AUC↑1.5-fold Dose: insufficient data	No data
Amprenavir (APV)	-	Levels: APV AUC and Cmin increased Dose: APV 600-750 mg bid, LPV/r standard

Evidence:

Most Common Drug-Drug Interactions

- Marengoni Study:
- Evaluated prevalence and characteristics of ADRs from drug interactions
- 1014 ADRs analyzed
- 912 of the ADRs had direct drug interactions
- 31% considered major
- Most were hemorrhages (54%)
- Warfarin was most common drug involved

Evidence: How Much of an Impact are Drug – Drug Interactions?

- Becker et al Evaluated the incidence of adverse patient outcomes due to drug interactions, ED visits and admissions
- Meta-analysis:
 - 23 clinical trials reviewed (>80,000 patients)
 - 0.054% of ED visits
 - 0.57% of hospital admissions
 - 0.12% re-admissions
 - Elderly pooled analysis: 4.8% hospital admissions
 - Most common drugs involved: NSAIDS and CV Drugs
 - Most common symptom from drug interactions: GIB, hypotension

Evidence: How Much of an Impact are Drug – Drug Interactions?

- Goldberg et al- Analyzed drug-drug and drug-disease interactions in the ER setting, both teaching facility and community hospital
 - 205 patients analyzed
 - 3 or more medications in patients over the age of 50
 - 47% potential interactions identified
 - 21% confirmed drug interactions
 - Risk of interactions rose from 13% for patients taking 2 meds to 82% for patients taking 7 or more medications

Types of Drug-Drug Interactions



Pharmacodynamic: Receptor

Site Interaction

Pharmacokinetic: Based on change of drug shape

Absorption

Metabolism

Excretion


BOCA RATON REGIONAL HOSPITAL

Drug Interactions-Absorption

Concurrent therapy increases or decreases absorption of the drug

Suspect Drug	Affected Drug	Mechanism of Interaction
Pepcid	Saquinavir (Increase) Other HIV Meds	Increase of gastric pH
Proton Pump Inhibitors	Saquinavir (Increase) Other HIV Meds Pradaxa (decrease)	Increase of gastric pH
Cogentin Elavil Thorazine Bentyl Opioids	All Oral Drugs (decrease)	Slower absorption due to slower GI motility
Bile Acid Sequestrants (Questran)	Digoxin, Warfarin, Depakote, Amiodarone, SSRI's (decrease)	Bind to the affected drugs, affecting absorption

Concurrent therapy affects drugs metabolized by liver (CYTP450) increasing or decreasing effects of drugs



• Phase 1


- Oxidation Metabolism
- Enzymes act to introduce reactive and polar groups into their substrates
- Cytochrome P450
- Inactive metabolites
- Phase 2
 - Conjugation Metabolism
 - Active metabolites

PGx Drug Metabolism Enzymes (DMEs)

DMEs catalyze reactions that affect the absorption, distribution, metabolism, excretion of drugs

Cytochrome P450 system

- · Phase I metabolic system of the liver
- Metabolism of >85% of medications
- · Genetic variability affects pharmacokinetics



• Object Drug:

- Causative drug
- Inducer or Inhibitor
- Substrate Drug:
 - Drug that is affected by the object drug
 - May be increased or decreased in effect depending on the object drug's action

Which CYTP450 Enzymes Impact The Most Medications?

Cytochrome P540 1A2

Inhibitor	Substrates Affected	Inducer	Substrates Affected
Norvasc Tagamet Cipro Prozac Lopid Nizoral Procardia Primaquine Diprivan	Effects of: Aminophylline Flexeril Clozaril Cymbalta Estrogens Zyprexa Inderal Ropivacaine Theophylline	Tegretol Phenobarbital Primidone Rifampin	Effects of: Aminophylline Flexeril Clozaril Cymbalta Estrogens Zyprexa Inderal Ropivacaine Theophylline

Cytochrome P540 2C8/9

Inhibitor	Substrates Affected	Inducer	Substrates Affected
Amiodarone/Multaq Sustiva Plendil Statins (except pravastatin) Entresto Ibuprofen Avapro Nizoral Cozaar Cardene Norvir Rosiglitazone Sulfadiazine Bactrim	Effects of:CoregCelebrexProzacLescolFosphenytoinGlucotrolAmarylKetamineCozaarSingulairPhenytoinAvandiaSulfadiazineBactrimDemadexWarfarin	Carbamazepine Fosphenytoin Phenobarbital Phenytoin Primidone Rifampin	Effects of: Coreg Celebrex Prozac Lescol Fosphenytoin Glucotrol Amaryl Ketamine Cozaar Singulair Phenytoin Avandia Sulfadizine Bactrim Demadex Warfarin

Cytochrome P540 2D6

Inhibitor	Substrates Affected	Substrates Affected	No Kr
Amiodarone/Multaq Thorazine Tagamet Clozaril Cocaine Precedex Benadryl Benadryl Cymbalta Prozac Haldol Nizoral Lidocaine Methadone Cardene Paxil	Effects of: Elavil Abilify Capoten Coreg Thorazine Codeine DM Cymbalta Prozac Haldol Lidocaine Lopressor Bystolic Paxil Phenergan Diprivan Flomax	Effects of: Ultram: Ultram is a prodrug, and its active metabolite cant be activated without 2D6	Inducers

No Known Inducers of 2D6

Cytochrome P540 3A4

Inhibitor	Substrates Affected	Inducer	Substrates Affected
Amiodarone/Multaq Caffeine Tagamet Biaxin Cyclosporine Cardizem Erythromycin Diflucan Haldol Nizoral Lidocaine Cardene Noxafil Diprivan	Effects of:XanaxAmiodaroneNorvascAbilifyLipitorUltramTegretolLibriumKlonopinCyclosporineDexamethasoneCardizemSustivaEstrogensFentanylMevacor / ZocorBactrimEliquis	Tegretol Dexamethasone Phenytoin Pentobarbital Phenobarbital Rifabutin Rifampin	Effects of: Xanax Amiodarone Norvasc Abilify Lipitor Ultram Tegretol Librium Klonopin Cyclosporine Dexamethasone Cardizem Sustiva Estrogens Fentanyl Mevacor / Zocor Bactrim

Risk Factors for Drug Interactions

Newer Medications Being Produced Still Have Drug Interactions

Year	Drug	Used In	Effect of CYP450
2015	Genvoya	HIV	Substrate of 3A4 and 2D6
2015	Addyi	Hypoactive Sexual Desire Disorder in premenopausal women	Substrate of 3A4, 2D6, 2C9
2015	Entresto	CHF	Inhibitor of 2C9
2015	Corlanor	CHF	Substrate of 3A4
2015	Cresemba	Antifungal for IA, Mucormycosis	Inhibitor of 3A4, 2C19, 2C8/9 Substrate of 3A4, Induces 2C8/9
2015	Avycaz	Multi-Resistant Abx	Induces 2E1


- Five potential mechanisms exist for drug interactions at the renal level:
- Displacement of bound drug resulting in an increase in drug excretion via an increase in glomerular filtration;
- Competition at a tubular secretion site resulting in a decrease in drug excretion;
- Competition at the tubular reabsorption site resulting in an increase in drug excretion;
- A change in urinary pH and/or flow that may increase or decrease drug excretion depending on the pKa of the drug; and
- ✓ Inhibition of renal drug metabolism.

Bonate et al; Clinical Pharmacokinetics; 1998; May 34(5) pp375-404

Drug	Effect on Substrate	Mechanism
Thiazide Diuretics	Decrease lithium elimination, increase lithium levels and effect	Competition at tubular site reabsorption
NSAIDs	Decrease lithium elimination, increase lithium levels and effect	Inhibit prostaglandins, leading to decreased glomerular filtration of lithium
Acetazolamide	ASA	Inhibits tubular excretion of ASA
Urinary Alkalizers (NaBicarb, thiazides, Na or K citrate)	Increase ASA, PCN, cephalosporin, acyclovir elimination (acid drugs), decrease elimination of weak base drugs (cocaine)	These drugs require low pH for reabsorption, higher pH for elimination

Ion trapping

In presence of sodium bicarbonate, urine is alkaline and more excretion of acidic drug into urine



Clinical Pharmacokinetics December 1994, Volume 27, pp 447-461 BOCA RATON REGIONAL HOSPITAL

Weak Acids	рКа	W	eak Bases pKa	
Amoxicillin	2.4		Alprenolol	9.6
Acetazolamide	7.2		Allopurinol	9.4, 12.3
Ampicillin	2.5		Amphetamine	9.8
Aspirin	3.5		Atropine	9.7
Chlorothiazide	6.8, 9.4*		Chlorpheniramine	9.2
Ciprofloxacin	6.1, 8.7*		Cocaine	8.5
Cephalexin	3.6		Codeine	8.2
Ethacrynic acid	2.5		Diazepam	3.0
Furosemide	3.9		Diphenhydramine	8.8
Ibuprofen	4.4, 5.2*		Amoxicillin	7.4
Levodopa	2.3		Ephedrine	9.6
Methotrexate	4.8		Epinephrine	8.7
Methyldopa	2.2, 9.2*		Imipramine	9.5
Penicillamine	1.8		Lidocaine	7.9
Pentobarbital	8.1		Methadone	8.4
Phenobarbital	7.4		Methamphetamine	10.0
Phenytoin	8.3		Methyldopa	10.6
Propylthiouracil	8.3		Metoprolol	9.8
Salicylic acid	3.0		Morphine	7.9
Sulfadiazine	6.5		Nicotine	7.9, 3.1*
Sulfapyridine	8.4		Norepinephrine	8.6
Theophylline	8.8	Π	Phenylephrine	9.8
Tolbutamide	5.3		Pilocarpine	6.9, 1.4*
Warfarin	5.0		Pseudoephedrine	9.8
* denotes more than one ionizable group				

BRRH Impact to Physicians? Most Common Medications Prescribed

Drug	Increase or Decreases:	Possible Effects:
Amiodarone Or Multaq	Inc levels of class 1A, III antiarrhythmics Canabis Digoxin Coreg Vaprisol Pradaxa Cerebyx / Dilantin "Statins", except prava Claritin Bystolic Warfarin Dec levels of Ultram Plavix	Inc QTC prolongation Inc effects of canabis Inc side effects Bradycardia, hypotens Inc sodium rapidly Bleeding Inc levels Myopathy, rhabdo Inc QTC prolongation Bradycardia, hypotens Inc INR Increased pain / failed effic Failed anti-platelet tx
Flagyl	Inc the effects of Ethanol Warfarin	Disulfiram-effects Increased INR

Drug	Increase or Decreases:	Possible Effects:
Ultram	Inc effects of Tegretol Zyvox warfarin SSRIs	Inc CNS depression Serotonin syndrome Inc INR Serotonin syndrome
NSAIDs	Inc effects of Aminoglycosides Digoxin Lithium MTX Quinolones Vancomycin	Inc risk of nephrotoxicity Inc levels, side effects Inc lithium levels, effects Inc levels, risk of toxicity QTC prolongation, neuro Inc levels
PPIs – Prilosec	Inc effects of Coreg Celexa Cerebyx Warfarin Dec effects of Plavix Pradaxa	Hypotension, bradycardia QTC prolongation CV events Inc INR CV events Bleeding

Drug	Increase or Decreases:	Possible Effects:
Quinolones	Inc levels of Tegretol Cymbalta MTX Theophylline Warfarin Dec levels of Cerebyx/Phen	Inc CNS depression Inc risk of MTX toxicity Toxicy Inc INR Dec levels
Diflucan	Inc effects of Eliquis Statins, except pravastatin Pulmicort Calcium Channel Blockers Coreg Fentanyl	Bleeding Rhabdo, myopathy Bradycardia, hypotension Bradycardia, hypotension Inc CNS/resp depression

Drug	Increase or Decreases:	Possible Effects:
Macrolide Antibiotics ? Azithromycin?	Inc effects of Statins Eliquis, Pradaxa, and Xarelto Pulmicort Calcium channel blockers Digoxin Fentanyl and Versed Theophylline Warfarin	Rhabdo, myopathy Bleeding Bradycardia, hypotension Inc levels, side effects Inc CNS depression Inc levels, toxicity Inc INR
Statins	Inc effects of warfarin	Inc INR

Gender Disposition for Drug Interaction Potential

Women and men are not equal in :

- ✓ % of body fat
 - Affects lipophilic drug interaction potential, involving opiods and benzodiazepines

Drug Metabolism

 Hepatic elimination of drugs is variable, and more likely to cause drug interactions

	Table 1. CYP450 Enzymes and Their Sex-Dependent Activity			
ו	CYP Enzyme	Enzyme Activity	Example Drugs	Other Characteristics
	1A2	M > W	Clozapine, olanzapine	Suppressed activity during pregnancy
	2A6	W > M	Nicotine, coumarin	Increased activity in female users of oral contraceptives
	2B6	W > M	Bupropion, tamoxifen	Activity: Hispanic women > Caucasian or African-American women
	209	M = W	Imipramine, phenytoin	Increased activity during pregnancy
	2C19	M = W	Imipramine, topiramate	Decreased activity during pregnancy or use of oral contraceptives
e	2D6	Mostly W > M	Codeine, fluoxetine, haloperidol	Increased activity during pregnancy
	3A4	Mostly W > M	Cyclosporine, erythromycin, nimodipine	Increased activity during pregnancy
	M: men; W: women. Source: References 16-24.			

Genetic Disposition for Drug Interaction Potential

CYP450 Sub Enzyme	Substrate	% Clearance From Norm
CYP2C9, genetics leading to intermediate or poor metabolizers	Celebrex Phenytoin Avapro Warfarin	-30% to -70% -33% to -88% -39% -42% to -90%
CYP2C19, genetics leading to intermediate or poor metabolizers	Prilosec Plavix	-37% to -76% -40% to -66%
CYP2D6, genetics leading to poor metabolizers or even ultrametabolizers	Lopressor Ultram	-32% to +160% -31% to -87%

POTENTIAL DRUG INTERACTIONS INCREASE BASED ON GENETICS

Westervelt, Paul et al P&T Sept 2014, Vol. 39 No. 9 630-638



Food-Drug Interactions



Food	Increase or Decreases:	Possible Effects:
Grapefruit	Inc effects of drugs metabolized by CYP3A4	Toxicity!
Tyramine Products: wine, chocolate, cheese, hotdogs, draft beer (bottle or canned ok),	Increase effects of MAOinhibitors by inhibiting breakdown of tyramine: Zyvox, Nardil, Parnate, etc	Increased hypertension
Green Leafy Vegetables	Dec effects of warfarin by increased Vit K enriched contents	Decreased INR
Natural Black Licorice (Glycyrrhiza)	Incr effects of digoxin by decreasing K+ levels and Inc Na+	Dig toxicity
Salt Substitutes	Dec effects of digoxin by increased K+ from salt substitutes	Lack of dig efficacy, exacerbation of CHF

A Word About Herbals



BOCA RATON REGIONAL HOSPITAL

A Word About Herbals

Table 4. Possible Herb-Drug Interactions.

Herbal agent	Interacting drugs	Clinical effect
Danshen (Salvia miltiorrhiza)	Warfarin	Bleeding
Dong quai	Warfarin	Bleeding
Ephedra	Caffeine, decongestants	Sympathomimetic toxidrome (hypertension, tachycardia, CNS, CVS stimulation)
Garlic	Warfarin	Lowers blood levels
	Chlorpropamide	Hypoglycemia
Ginkgo biloba	Aspirin, clopidogrel, dipyridamole, ticlopidine, warfarin, heparin	Bleeding
	Thiazide diuretic	Elevated blood pressure
	Trazodone	Coma
	Morphine	Lack of effect
Ginseng	Warfarin, ethanol	Lowers blood levels
	Phenelzine	Induces mania
Kava	Benzodiazepines, sedative-hypnotics	CNS depression
	Levodopa	Increased "off" periods
St. John's wort	Antidepressants	Serotonergic stimulation (theoretical)
	Cyclosporin	Decreased effect (cytochrome p450 inducer)
	Digoxin	Decreased serum level
Valerian	Anxiolytics	CNS sedation

What Can We Do?

- 1. Minimize prescriptions (decrease polypharmacy)
- 2. Accurate medication history
- 3. Discourage OTC medications that are on this list
- 4. Caution with herbal medications

What Can We Do? Beware of OTCs










BOCA RATON REGIONAL HOSPITAL

What Can We Do?

- Electronic Medical Record Utilization
 - BRRH currently uses First Data Bank for pharmacy review of drug interactions
 - Physicians see absolute contraindications upon order entry (decision made by Medical Staff)
 - Develop a systematic process for development of standard set of drug drug interactions for clinical decision support

What Can We Do?

• Electronic Medical Record Utilization



Each institution decides which levels of drug interactions to be set

Drawbacks: Alert fatigue!

Physicians only see grade X contraindications in current CPOE

Tilson et al Am J Health-Syst Pharm ; April 2016; Vol 73, No 8 576-585

BRRH Drug Interaction Notification to Physicians



Local Drug Interactions References for Physicians

Phone / Pad devices – Epocrates, Micromedex
BRRH Intranet – Pharmacy Tab Lexicomp

 Direct drug input with all possible interactions

Up to Date – More focused on the complications of the interaction, some more common drug-drug

Thank You

BOCA RATON REGIONAL HOSPITAL